The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL (Q57024599)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

title

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

main subject

duvelisib

0 references

phase III clinical trial

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Paolo Ghia

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

25

Stephan Stilgenbauer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

21

Amanda F Cashen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

author name string

Ian W Flinn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Peter Hillmen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Marco Montillo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Zsolt Nagy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Árpád Illés

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Gabriel Etienne

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Bryone J Kuss

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Constantine S Tam

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Zoltán Gasztonyi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Fritz Offner

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Scott Lunin

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Francesco Bosch

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Matthew S Davids

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Nicole Lamanna

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Ulrich Jaeger

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Florence Cymbalista

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Craig A Portell

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Alan P Skarbnik

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

David T Weaver

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Virginia M Kelly

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Barry Turnbull

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

language of work or name

English

0 references

publication date

4 October 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

26 April 2020

http://eprints.whiterose.ac.uk/140594

content deliverer

White Rose Research Online

object has role

postprint

start time

4 October 2019

0 references

published in

Blood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

volume

132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

page(s)

2446-2455

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

26 April 2020

cites work

1 reference

12 December 2020

Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing

1 reference

12 December 2020

A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

1 reference

12 December 2020

Revised response criteria for malignant lymphoma

1 reference

12 December 2020

Management of infectious complications in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

12 December 2020

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

12 December 2020

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

1 reference

12 December 2020

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

1 reference

12 December 2020

Update on therapy of chronic lymphocytic leukemia

1 reference

12 December 2020

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

1 reference

12 December 2020

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

1 reference

12 December 2020

Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia

1 reference

12 December 2020

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

1 reference

12 December 2020

Infectious complications in chronic lymphocytic leukemia

1 reference

12 December 2020

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models

1 reference

12 December 2020

Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers

1 reference

12 December 2020

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

12 December 2020

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

12 December 2020

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

1 reference

12 December 2020

Management of adverse events associated with idelalisib treatment: expert panel opinion

1 reference

12 December 2020

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

1 reference

12 December 2020

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

1 reference

12 December 2020

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

1 reference

12 December 2020

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides

1 reference

12 December 2020

Idelalisib-associated Colitis: Histologic Findings in 14 Patients.

1 reference

12 December 2020

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival

1 reference

12 December 2020

The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia

1 reference

12 December 2020

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

1 reference

12 December 2020

Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?

1 reference

12 December 2020

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

1 reference

12 December 2020

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

1 reference

12 December 2020

PI3Kγ is a molecular switch that controls immune suppression

1 reference

12 December 2020

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

1 reference

12 December 2020

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

1 reference

12 December 2020

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.

1 reference

12 December 2020

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

1 reference

12 December 2020

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

1 reference

12 December 2020

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.

1 reference

12 December 2020

Systematic review of infectious events with the BTK inhibitor ibrutinib in the treatment of haematologic malignancies.

1 reference

12 December 2020

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

1 reference

12 December 2020

10.1182/BLOOD-2018-05-850461

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30287523%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference